Related Experiment Video
Updated: Dec 7, 2025
Endovascular Perforation Model for Subarachnoid Hemorrhage Combined with Magnetic Resonance Imaging MRI
Published on: December 16, 2021
Middle Meningeal Artery Embolization in Chronic Subdural Hematoma: Implications of Pathophysiology in Trial Design
Pouria Moshayedi1, David S Liebeskind1
1Department of Neurology, UCLA Comprehensive Stroke Center, University of California, Los Angeles, Los Angeles, CA, United States.
Insights
Middle meningeal artery (MMA) embolization shows promise for treating chronic subdural hematoma (cSDH). This minimally invasive approach may reduce recurrence rates, offering a new therapeutic avenue for this debilitating condition.
Area of Science:
- Neurosurgery
- Interventional Radiology
- Neurology
Background:
- Chronic subdural hematoma (cSDH) presents a significant clinical challenge due to high recurrence rates post-surgical evacuation.
- Understanding the pathophysiology of cSDH is crucial for developing effective treatments.
Purpose of the Study:
- This review explores middle meningeal artery (MMA) embolization as a treatment for cSDH.
- To evaluate the current evidence and future directions for MMA embolization in cSDH management.
Main Methods:
- Review of existing literature on MMA embolization for cSDH.
- Discussion of the pathophysiological rationale for MMA embolization in cSDH.
Main Results:
- MMA embolization is presented as a potential method to resolve venous hemorrhage by ceasing arterial flow.
- Current evidence supporting MMA embolization for cSDH is discussed.
Conclusions:
- Further research and clinical trials are needed to establish the efficacy of MMA embolization.
- Multimodal imaging and cSDH sampling can elucidate treatment mechanisms and guide patient selection for MMA embolization.
Abstract:
Background: Chronic subdural hematoma (cSDH) is a debilitating condition with a high rate of recurrence after surgical evacuation. Summary: This review is focused on middle meningeal artery (MMA) embolization to treat cSDH. We discuss the underlying pathophysiology of chronic subdural hematoma and how cessation of arterial flow may resolve a venous hemorrhage. We also present the current evidence for MMA embolization and the roadmap for future trials. Conclusion: Frequent multimodal imaging and cSDH sampling would enable us to understand mechanisms of MMA embolization in cSDH treatment and therefore improve our ability to offer MMA embolization to the eligible population.
